Breaking News! A Novel Drug Shows Promising Results against the New Coronavirus (SARS-CoV-2).


On February 24, 2020, an unprecedented study published in the Journal of Biological Chemistry found that novel antiviral drug Remdesivir could be used against new coronavirus or the deadly COVID-19.


The novel antiviral drug Remdesivir is a member in the class of nucleotide analogs. Back in 2014, it was developed by Gilead Sciences as a treatment for Ebola virus disease and Marburg virus infections.


According to the authors of the study from the University of Alberta, the Remdesivir had previously been found to be effective against other similar viruses such as MERS and SARS, which are also coronaviruses and are structurally similar to COVID-19. The team, therefore, wanted to test the efficacy of Remdesivir against the new COVID-19 strain.

Comments

Post a Comment

Popular posts from this blog

First Living Robots from Stem Cells. Are We Dreaming?

Most of us are aware of stem cells' remarkable capacity to develop into other cells such as blood, brain, or liver cells. However, did you know that stem cells can be transformed into living robots? An extraordinary research published in the Proceedings of the National Academy of Sciences on January 13, 2020, shown that frog stem cells may be transformed into the world's first living, self-healing robots. These living machines are known as xenobots because they are derived from the stem cells of the African clawed frog (Xenopus laevis), and the term "xenobots" comes from the combination of Xenopus and robots. These xenobots are projected to have a significant influence not just on targeted therapy, but also on human health and wellbeing. References https://www.pnas.org/content/early/2020/01/07/1910837117 https://edition.cnn.com/2020/01/13/us/living-robot-stem-cells-intl-hnk-scli-scn/index.html https://www.livescience.com/frogbots-living-robots.html https://www.uvm.edu...
Read more

Researchers Found an Indicator of Severity of COVID-19. Soluble Circulating Protein May Be the Clue.

A new study published on April 30, 2020 in Journal Critical Care   indicated that the protein soluble urokinase plasminogen activator receptor (suPAR) may assist researchers anticipate who is likely to have more severe COVID-19 symptoms. In other words, suPAR may be regarded as a proxy measure of COVID-19 severity. The researchers examined data from 57 patients at Greece's University of Athens Medical School and 5 COVID-19 patients at Rush University Medical Center. They discovered that patients with greater amounts of suPAR in their blood needed intubation sooner than individuals with lower levels of suPAR. This is the first publication to suggest that suPAR is higher in COVID-19 and may be indicative of COVID-19 severity. This study is important not just for identifying patients who are more likely to require immediate intensive care, but also for identifying individuals who can safely manage the condition at home. References https://www.medicalnewstoday.com/articles/study-sugges...
Read more

Kawasaki-like Disease is seen in Some Children with COVID-19

On May 13, 2020, a stunning research published in Lancet   discovered that unique severe Kawasaki-like disease in children caused by COVID-19 was reported in several nations including Italy and the United Kingdom. This highlights the possibility of a link between COVID-19 and Kawasaki-like illness. Although SARS-CoV-2 infection affects children infrequently, a tiny fraction of them develop Kawasaki-like illness. Kawasaki illness, a rare acute paediatric vasculitis, mostly affects children under the age of five. Coronary artery aneurysms are the most common complication of Kawasaki illness. The presence of persistent fever, lymphadenopathy, conjunctival injection, and alterations to the mucosae and extremities is used to make the diagnosis (swollen extremities). The absence of a good diagnostic test impedes the diagnosis of Kawasaki illness, which is most reliant on laboratory and clinical criteria. Ongoing research is attempting to determine the link between COVID-19 and the Kawasa...
Read more